Search

Your search keyword '"Katai H"' showing total 446 results
Start Over Author "Katai H"

Refine your results

446 results on '"Katai H"'

51. A full genome scan for gastric cancer

Author

Aoki, M, Yamamoto, K, Noshiro, H, Sakai, K, Yokota, J, Kohno, T, Tokino, T, Ishida, S, Ohyama, S, Ninomiya, I, Uesaka, K, Kitajima, M, Shimada, S, Matsuno, S, Yano, M, Hiratsuka, M, Sugimura, H, Itoh, F, Minamoto, T, Maehara, Y, Takenoshita, S, Aikou, T, Katai, H, Yoshimura, K, Takahashi, T, Akagi, K, Sairenji, M, Yamamura, Y, and Sasazuki, T

Published
2005

55. EFFECTIVENESS OF THE ALGORITHM OF DEPTH DIAGNOSIS FOR SUPERFICIAL BARRETT'S ADENOCARCINOMA

Author

Yoshinaga, S, additional, Oda, I, additional, Furutani, K, additional, Hihara, D, additional, Koga, M, additional, Ito, T, additional, Cho, H, additional, Yamada, M, additional, Abe, S, additional, Nonaka, S, additional, Suzuki, H, additional, Saito, Y, additional, Daiko, H, additional, Katai, H, additional, Taniguchi, H, additional, and Sekine, S, additional

Published
2019
Full Text
View/download PDF

60. Diagnosis of invasion depth in resectable advanced gastric cancer for neoadjuvant chemotherapy: An exploratory analysis of JCOG1302A

Author

Sato, Y., primary, Mizusawa, J., additional, Nakamura, K., additional, Fukagawa, T., additional, Katai, H., additional, Haruta, S., additional, Yamada, M., additional, Takagi, M., additional, Tamura, S., additional, Yoshimura, T., additional, Inada, T., additional, Hirabayashi, N., additional, Wada, I., additional, Kodera, Y., additional, Tokunaga, M., additional, Yoshikawa, T., additional, Boku, N., additional, Sano, T., additional, Sasako, M., additional, and Terashima, M., additional

Published
2018
Full Text
View/download PDF

64. 2221 Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer; short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG 0501)

Author

Terashima, M., primary, Iwasaki, Y., additional, Mizusawa, J., additional, Katayama, H., additional, Nakamura, K., additional, Katai, H., additional, Yoshikawa, T., additional, Ito, S., additional, Kaji, M., additional, Kimura, Y., additional, Hirao, M., additional, Yamada, M., additional, Kurita, A., additional, Takagi, M., additional, Goto, M., additional, Takagane, A., additional, Yabuzaki, H., additional, Hirabayashi, N., additional, Sano, T., additional, and Sasako, M., additional

Published
2015
Full Text
View/download PDF

66. Prognostic factors for survival in patients with pT1 N+ or T2-3 N0 gastric cancer in Japan.

Author

Tokunaga, M., Ito, S., Yoshikawa, T., Nunobe, S., Fukagawa, T., Misawa, K., Cho, H., Katai, H., Sano, T., and Terashima, M.

Subjects
STOMACH cancer patients, STOMACH cancer treatment, CANCER relapse, PROGNOSTIC tests, ADJUVANT treatment of cancer, LYMPHADENECTOMY, GASTRECTOMY
Abstract

Background The outcome for pT1 N+ or pT2-3 N0 gastric cancer is favourable, but some patients suffer from recurrent disease. The aim of this study was to identify prognostic factors in patients with pT1 N+ or pT2-3 N0 gastric cancer. Methods This was a multicentre, retrospective cohort study. All patients with pT1 N+ or pT2-3 N0 gastric cancer who underwent curative gastrectomy at five high-volume, specialized cancer centres in Japan between 2000 and 2008 were included. Demographic, clinical, surgical and pathological data were collected. Independent prognostic factors were identified using a Cox proportional hazards regression model. Results Some 1442 patients were included. The 5-year overall survival rate for patients with pT1 N+ or pT2-3 N0 gastric cancer was 92·0 per cent. Multivariable analysis for overall survival identified age (hazard ratio ( HR) 2·67, 95 per cent c.i. 2·09 to 3·43), sex ( HR 0·57, 0·39 to 0·83) and clinical tumour depth ( cT) ( HR 1·45, 1·06 to 1·98) as independent prognostic factors. Conclusion Survival of patients with pT1 N+ or pT2-3 N0 gastric cancer is good. Age 65 years or above, male sex and cT2-4 category are associated with worse overall survival. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

71. Pfetin as a Prognostic Biomarker in Gastrointestinal Stromal Tumor: Novel Monoclonal Antibody and External Validation Study in Multiple Clinical Facilities

Author

Kikuta, K., primary, Gotoh, M., additional, Kanda, T., additional, Tochigi, N., additional, Shimoda, T., additional, Hasegawa, T., additional, Katai, H., additional, Shimada, Y., additional, Suehara, Y., additional, Kawai, A., additional, Hirohashi, S., additional, and Kondo, T., additional

Published
2009
Full Text
View/download PDF

96. Correspondence.

Author

Altomare, D.F., Woodward, A., Sillin, L.F., Wyncoll, D.L.A., Beale, R.J., McKay, C.J., Imrie, C.W., Parks, R.W., Diamond, T., Potter, M.A., SenGupta, S.B., Yiu, C.Y., Boulos, P.B., Delhanty, J.D.A., Lehnert, Th., Sano, T., Sasako, M., Katai, H., and Maruyama, K.

Subjects
SURGERY, GASTRECTOMY
Abstract

Provides comments and answers to questions from readers dealing with articles that were published in the periodical `British Journal of Surgery.' Confirmation to the claim that oral erythromycin improves gastrointestinal motility and transit after subtotal but not total gastrectomy for cancer; Question on prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis.

Published
1998
Full Text
View/download PDF

97. The genomic damage estimated by arbitrarily primed PCR DNA fingerprinting is useful for the prognosis of gastric cancer

Author

Suzuki, K., Ohnami, S., Tanabe, C., Sasaki, H., Yasuda, J., Katai, H., Yoshimura, K., Terada, M., Perucho, M., and Yoshida, T.

Abstract

Background & Aims:: Genomic instability and the accompanying alteration of cancer genes play a major role in tumorigenesis. We evaluated the prognostic significance in gastric cancer of the degree of accumulation of relative genomic damage, assessed by arbitrarily primed polymerase chain reaction DNA fingerprinting. Methods:: Genomic damage was assessed by comparative analysis of paired normal and tumor tissue DNA fingerprints. The total number of alterations, scored as decreases and increases of band intensity with 2 arbitrary primers, were used as an estimation of the genomic damage fraction in 74 primary gastric cancers. Increases in DNA copy number were also analyzed by array comparative genomic hybridization in a subset of 30 cases. Results:: The number of altered bands varied among the tumors from none or a few to more than one third of the approximately 40 fingerprint bands. The relative values of genomic damage were consistent with the quantitative chromosomal alterations observed by array comparative genomic hybridization. When the tumors were stratified into 2 groups-above or below the cutoff of 0.22 for average genomic damage fraction-genomic damage fraction was a valuable prognostic indicator regardless of microsatellite instability status. Multivariate Cox analysis showed that the genomic damage fraction was a prognostic indicator, as well as a stage indicator (P = 0.0189). Survival was significantly diminished in tumors with a genomic damage fraction >0.22 (P = 0.0009). Moreover, in the 46 curative cases, genomic damage fraction was the only independent factor for predicting survival (P = 0.0061). Conclusions:: Our results indicate that the degree of genomic damage estimated by arbitrarily primed polymerase chain reaction fingerprinting is a useful prognostic indicator for gastric cancer.

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results